Two new studies, one from the United States and one from Canada, suggest that the oral antiviral drug Paxlovid (nirmatrelvir-ritonavir) is effective in lowering the odds of hospitalization or death from the SARS-CoV-2 Omicron subvariant.
Based on the data from Afghanistan’s Ministry of Public Health Expanded Programme on Immunization, the campaign covered 329 districts in all 34 provinces of the country – with 4,341 vaccination teams comprised of four members on each team.
